---
company: Starling Oncology, Inc.
ticker: DFPH
form: 8-K
filed: 2026-08-06
accession: 0001079973-26-001006
source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/
---

# Starling Oncology (DFPH) earnings release, August 6, 2026

Starling Oncology, Inc. (DFPH) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/)

Starling Oncology Reports Second Quarter

2026 Financial Results and Updates Full-Year 2026 Guidance

CERRITOS,

Calif., August 6, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.

Recent

Operational Highlights

Second Quarter 2026 Financial Highlights

All comparisons are to the quarter ended

June 30, 2025 unless otherwise noted

*Adjusted EBITDA is a non-GAAP measure and the reconciliation is included in the Financial Information; Non-GAAP Financial Measures section below.

Management

Commentary

Daniel Virnich, CEO of Starling, commented, "The second quarter of 2026 was a milestone quarter for our company, with revenue up 35% year over year and Adjusted EBITDA turning positive in Q2. We signed our first delegated contracts outside of Florida, in Nevada and Oregon, and reached an exclusivity agreement with one of our largest partners across California. Both of these achievements will drive robust capitated revenue growth going forward.

In mid-August, we are launching our new provider portal, Starling Oncology NexusTM, which we expect will deepen provider engagement and further support adherence to our clinical pathways. Given this momentum, we are raising our full-year outlook, and remain confident in our path to sustained positive Adjusted EBITDA as we move forward as Starling Oncology."

Updated Outlook for

Fiscal Year 2026

* The Company uses Adjusted EBITDA, Medical

Loss Ratio (MLR), and Free Cash flow, each a non-GAAP measure, as an additional tool to assess its operational and financial performance.

See "Financial Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception provided under

Regulation S-K, STLN is not reasonably able to provide a quantitative reconciliation for forward-looking information of Adjusted EBITDA,

MLR and Free Cash flow to net (loss) income and net cash provided by operations, respectively, the most directly comparable GAAP financial measures, without unreasonable efforts due to uncertainties regarding capitated lives, direct costs, taxes, capital expenditures, share-based compensation, change in fair value of liabilities, unrealized (gains) losses on investments, consulting and legal fees, transaction costs and other non-cash items. The variability of these items could have an unpredictable, and potentially significant, impact on STLN’s future GAAP financial results.

The Company expects approximately $150 million in capitated revenue in 2026. The Company also anticipates that Medical Loss Ratio, discussed under “Financial Information; Non-GAAP

Financial Measures” below, will be in the range of 80% to 90% in the next twelve months.

Third Quarter of 2026 Outlook

For the third quarter of 2026, we anticipate

Adjusted EBITDA of $500 thousand to $1.5 million, as the Company onboards and ramps our Florida delegated lives.

The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating or economic environment, nor does it take into account the impact of STLN's acquisitions, dispositions or financings. STLN's outlook assumes a largely stable global market, which would likely be negatively impacted if recent tariff rate increases and exchange rate changes persist and adversely affect world trade. The outlook information included in this press release represents management's current estimates as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Forward-Looking Statements included in this release.

Management does not assume any obligation to update these estimates other than as required by applicable law.

Webcast and Conference

Call

STLN will host a conference call on Thursday,

August 6, 2026 at 5:30 p.m. (Eastern Time) to discuss second quarter results and management’s outlook for future financial and operational performance.

The conference call can be accessed live over the phone by dialing 1-800-225-9448, or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be available until Thursday, August 20, 2026..

About The Oncology Institute, Inc.

Founded in 2007, Starling Oncology, Inc. (NASDAQ: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute,

Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly

Twitter), or Bluesky.

Forward-Looking Statements

This press release includes contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended

(the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking... (truncated)rds such as “preliminary,” “believe,” “may,” “will,”

“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”

“would,” “plan,” “project,” “predict,” “potential,” “guidance,”

“approximately,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of STLN and are not predictions of actual performance. These forward-looking statements must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of

STLN. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2026 full fiscal year outlook and the Q3 2026 outlook with respect to Adjusted EBITDA discussed herein, the outcome of judicial and administrative proceedings to which STLN may become a party or investigations to which STLN may become or is subject that could interrupt or limit STLN’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in STLN’s patient or payors' preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of a cybersecurity incident affecting a software provider on STLN’s business; and those factors discussed in the documents of STLN has filed, or will file, with the SEC, including the Item 1A. "Risk Factors" section of STLN's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 12, 2026 and any subsequent filed

Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. If these risks materialize or STLN’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that

STLN currently is evaluating or does not presently know, or that STLN currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect STLN’s plans or forecasts of future events and views as of the date of this press release. STLN anticipates that subsequent events and developments will cause STLN’s assessments to change. STLN does not undertake any obligation to update any of these forward-looking statements other than as required by applicable law. These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements and readers are cautioned to not place undue reliance on these forward looking statements.

Financial Information; Non-GAAP Financial

Measures

STLN uses certain financial information and data, such as Adjusted

EBITDA, Medical Loss Ratio (MLR), and Free Cash Flow, that have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”) when reporting and discussing its financial results. STLN’s non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with STLN’s financial statements and the related notes thereto.

Medical Loss Ratio (MLR)

: STLN defines

MLR as our total direct costs related to capitated contracts divided by the total capitated revenue.

STLN believes that the use of Medical Loss Ratio (MLR) provides management with an additional tool to assess our operational efficiency and commitment to value, to plan and forecast future periods, and to understand the factors and trends in our premium spending. The MLR is utilized by peers across the health industry, and we believe it is helpful to investors in measuring our financial performance and comparing our performance to other health providers. The principal limitation of MLR is that its calculation, relies on definitions and allocations that require management's judgment and may not capture all nuances of our administrative efficiency or investment in long-term infrastructure. Direct Costs for capitation include clinical payroll,

IV drug costs, network medical expense, and medical supplies.

Free Cash Flow

: STLN defines Free

Cash Flow as net cash flow provided by (used in) operations plus cash paid for interest, less capital expenditures. STLN believes that the use of Free Cash Flow provides management with an additional tool to assess the Company's financial performance, evaluate its ability to generate cash from operations, and plan for future investments and obligations. Free Cash Flow is useful in understanding the cash available for strategic initiatives. We believe that Free Cash Flow is helpful to investors in measuring our financial performance and comparing our performance to our peers. Free Cash Flow has important limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP...usted EBITDA:

STLN defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, interest, taxes, non-cash add-backs comprised of one-time write-offs and non-cash rent expense, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized gains or losses on investments and other adjustments to add-back the following: consulting and legal fees related to acquisitions, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temporary labor and recruiting charges to build out our corporate infrastructure.

STLN believes that the use of Adjusted EBITDA provides management with an additional tool to assess our operations and results of our performance, to plan and forecast future periods, and factors and trends. We believe that Adjusted EBITDA is helpful to investors in measuring our financial performance and comparing our performance to our peers. Adjusted EBITDA has important limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP.

A reconciliation of total direct costs and revenue related to capitated contracts to MLR, net cash flow provided by (used in) operations to Free Cash Flow, and net loss to Adjusted

EBITDA, the most comparable GAAP metrics, is set forth below:

Consolidated

Balance Sheets (Unaudited)

(in thousands except share data)

Consolidated Statements of Operations (Unaudited)

(in thousands except share data)

Consolidated

Statements of Cash Flows (Unaudited)

(in thousands)

Contacts

Media

The Oncology Institute, Inc.

Daniel Virnich, MD danielvirnich@starlingoncology.com

(562) 735-3226 x 81125

Investors

ICR Strategic Communications investors@icrinc.com

## Financial statements

### Income Statement (Adjusted EBITDA Reconciliation (in thousands))

| | Adjusted EBITDA Reconciliation – Three Months Ended June 30, – 2026 | Adjusted EBITDA Reconciliation – Three Months Ended June 30, – 2025 | Adjusted EBITDA Reconciliation – Change – $$ | Adjusted EBITDA Reconciliation – Change – % | Adjusted EBITDA Reconciliation – Six Months Ended June 30, – 2026 | Adjusted EBITDA Reconciliation – Six Months Ended June 30, – 2025 | Adjusted EBITDA Reconciliation – Change – $$ | Adjusted EBITDA Reconciliation – Change – % |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net loss | -9,789 | -17,009 | 7,220 | 42.4% | -12,281 | -36,594 | 24,313 | 66.4% |
| Depreciation and amortization | 1,838 | 1,805 | 33 | 1.8% | 3,454 | 3,589 | -135 | -3.8% |
| Interest expense, net | 1,859 | 1,870 | -11 | -0.6% | 3,793 | 7,440 | -3,647 | -49.0% |
| Income tax and other taxes | 86 | -61 | 147 |  | 129 | -61 | 190 |  |
| Non-cash addbacks | -36 | 2,222 | -2,258 | -101.6% | -284 | 2,059 | -2,343 | -113.8% |
| Share-based compensation | 1,070 | 752 | 318 | 42.3% | 2,756 | 2,210 | 546 | 24.7% |
| Changes in fair value of liabilities | 3,237 | 4,040 | -803 | -19.9% | -1,927 | 7,392 | -9,319 | -126.1% |
| Unrealized loss on investments |  |  |  |  |  | 6 | -6 | -100.0% |
| Post-combination compensation expense |  | 13 | -13 | -100.0% |  | 26 | -26 | -100.0% |
| Consulting fees | 1,814 | 506 | 1,308 | 258.5% | 2,087 | 839 | 1,248 | 148.7% |
| Infrastructure and workforce costs | 150 | 1,771 | -1,621 | -91.5% | 64 | 3,895 | -3,831 | -98.4% |
| Transaction costs |  | 1 | -1 |  |  | 1 | -1 | -100.0% |
| Adjusted EBITDA | 229 | -4,090 | 4,319 | 105.6% | -2,209 | -9,198 | 6,988 | 76.0% |

### Income Statement (Three Months Ended June 30, — (in thousands except share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | Patient services | 58,827 | 55,891 | 117,914 | 108,959 |
| Revenue | Specialty Pharmacy | 98,608 | 62,573 | 186,149 | 111,866 |
| Revenue | Clinical trials & other | 3,847 | 1,338 | 4,660 | 3,383 |
| Revenue | Total operating revenue | 161,282 | 119,802 | 308,723 | 224,208 |
| Operating expenses | Direct costs – patient services | 56,771 | 51,150 | 110,154 | 98,230 |
| Operating expenses | Direct costs – specialty pharmacy | 77,346 | 51,086 | 148,089 | 90,949 |
| Operating expenses | Direct costs – clinical trials & other |  | 65 |  | 279 |
| Operating expenses | Selling, general and administrative expense | 29,943 | 26,907 | 58,155 | 52,283 |
| Operating expenses | Depreciation and amortization | 1,838 | 1,805 | 3,454 | 3,589 |
| Operating expenses | Total operating expenses | 165,898 | 131,013 | 319,852 | 245,330 |
| Operating expenses | Loss from operations | -4,616 | -11,211 | -11,129 | -21,122 |
| Other non-operating expense (income) | Interest expense, net | 1,859 | 1,870 | 3,793 | 7,440 |
| Other non-operating expense (income) | Change in fair value of derivative warrant liabilities | -6 | 53 | -174 | 96 |
| Other non-operating expense (income) | Change in fair value of conversion option derivative liabilities | 3,243 | 3,987 | -1,753 | 7,296 |
| Other non-operating expense (income) | Other, net | 77 | 19 | -714 | 771 |
| Other non-operating expense (income) | Total other non-operating expense (income) | 5,173 | 5,929 | 1,152 | 15,603 |
| Other non-operating expense (income) | Loss before provision for income taxes | -9,789 | -17,140 | -12,281 | -36,725 |
| Other non-operating expense (income) | Income tax benefit (expense) |  | 131 |  | 131 |
| Other non-operating expense (income) | Net loss | -9,789 | -17,009 | -12,281 | -36,594 |
| Other non-operating expense (income) | Net loss attributable to common stockholders, basic and diluted | -8,241 | -13,991 | -10,330 | -30,072 |
| Net loss per share attributable to common stockholders: | Basic | -0.08 | -0.15 | -0.1 | -0.35 |
| Net loss per share attributable to common stockholders: | Diluted | -0.08 | -0.15 | -0.1 | -0.35 |
| Weighted-average number of shares outstanding: | Basic | 103,031,493 | 93,203,665 | 102,419,949 | 85,195,734 |
| Weighted-average number of shares outstanding: | Diluted | 103,031,493 | 93,203,665 | 102,419,949 | 85,195,734 |

### Balance Sheet (June 30, 2026 — (in thousands except share data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 41,094 | 33,565 |
| Current assets: | Accounts receivable, net | 66,349 | 58,998 |
| Current assets: | Other receivables | 360 | 322 |
| Current assets: | Inventories | 20,011 | 16,875 |
| Current assets: | Prepaid expenses and other current assets | 1,176 | 2,987 |
| Current assets: | Total current assets | 128,990 | 112,747 |
| Current assets: | Property and equipment, net | 10,583 | 10,684 |
| Current assets: | Operating right of use assets | 21,188 | 22,374 |
| Current assets: | Intangible assets, net | 9,585 | 11,015 |
| Current assets: | Goodwill | 7,230 | 7,230 |
| Current assets: | Other assets | 657 | 606 |
| Current assets: | Total assets | 178,233 | 164,656 |
| Current liabilities: | Accounts payable | 60,279 | 43,167 |
| Current liabilities: | Current portion of operating lease liabilities | 7,225 | 7,156 |
| Current liabilities: | Accrued expenses and other current liabilities | 27,435 | 20,639 |
| Current liabilities: | Total current liabilities | 94,939 | 70,962 |
| Current liabilities: | Operating lease liabilities | 17,384 | 19,131 |
| Current liabilities: | Derivative warrant liabilities | 89 | 264 |
| Current liabilities: | Derivative liabilities | 10,838 | 12,591 |
| Current liabilities: | Long-term debt, net of unamortized debt issuance costs | 79,867 | 77,400 |
| Current liabilities: | Other non-current liabilities | 30 | 28 |
| Current liabilities: | Total liabilities | 203,147 | 180,376 |
| Stockholders’ deficit: | Common Stock, 0.0001 par value, authorized 500,000,000 shares; 102,202,753 and 100,468,979 shares issued and outstanding at June 30, 2026 and 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 2025 | 10 | 10 |
| Stockholders’ deficit: | Additional paid-in capital | 259,795 | 256,708 |

### Cash Flow (Free Cash Flow Reconciliation (in thousands))

| | Free Cash Flow Reconciliation – Six Months Ended June 30, – 2026 | Free Cash Flow Reconciliation – Six Months Ended June 30, – 2025 | Free Cash Flow Reconciliation – Change – $$ | Free Cash Flow Reconciliation – Change – % |
|---|---:|---:|---:|---:|
| Net cash and cash equivalents provided by (used in) operating activities | 9,725 | -15,190 | 24,915 | 164.0% |
| Cash paid for interest | 1,756 | 2,158 | -402 | 18.6% |
| Purchases of property and equipment | -1,950 | -1,536 | -414 | -27.0% |
| Free Cash Flow | 9,531 | -14,568 | 24,099 | 165.4% |

### Cash Flow (Six Months Ended June 30, — (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net loss | -12,281 | -36,594 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Depreciation and amortization | 3,454 | 3,589 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Amortization of debt issuance costs and debt discount | 2,467 | 6,003 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Write-off of assets from clinical trials segment |  | 2,398 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Share-based compensation | 2,756 | 2,210 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Change in fair value of liability classified warrants | -174 | 96 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Change in fair value of liability classified conversion option derivatives | -1,753 | 7,296 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Deferred taxes |  | -32 |
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | Loss on disposal of property and equipment | 28 |  |
| Changes in operating assets and liabilities: | Accounts receivable | -7,351 | -8,969 |
| Changes in operating assets and liabilities: | Other receivables | -38 | -228 |
| Changes in operating assets and liabilities: | Inventories | -3,136 | -5,747 |
| Changes in operating assets and liabilities: | Prepaid expenses | 1,811 | 1,250 |
| Changes in operating assets and liabilities: | Other assets | -51 | 3 |
| Changes in operating assets and liabilities: | Accounts payable | 17,112 | 11,490 |
| Changes in operating assets and liabilities: | Change in operating leases | -492 | -120 |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | 7,353 | 2,262 |
| Changes in operating assets and liabilities: | Other non-current liabilities | 20 | -97 |
| Changes in operating assets and liabilities: | Net cash and cash equivalents provided by (used in) operating activities | 9,725 | -15,190 |
| Cash flows from investing activities: | Purchases of property and equipment | -1,950 | -1,536 |
| Cash flows from investing activities: | Proceeds from asset disposition |  | 126 |
| Cash flows from investing activities: | Net cash and cash equivalents used in investing activities | -1,950 | -1,410 |
| Cash flows from financing activities: | Proceeds from private placement, net of offering costs |  | 15,359 |
| Cash flows from financing activities: | Proceeds from employee stock purchase plan | 220 |  |
| Cash flows from financing activities: | Payments made for financing of insurance payments | -560 | -456 |
| Cash flows from financing activities: | Principal payments on long-term debt |  | -20,000 |
| Cash flows from financing activities: | Principal payments on financing leases | -17 | -20 |
| Cash flows from financing activities: | Common stock issued for options exercised | 111 | 2,340 |
| Cash flows from financing activities: | Net cash and cash equivalents provided by (used in) financing activities | -246 | -2,777 |
| Cash flows from financing activities: | Net increase (decrease) in cash and cash equivalents | 7,529 | -19,377 |
| Cash flows from financing activities: | Cash and cash equivalents at beginning of period | 33,565 | 49,669 |
| Cash flows from financing activities: | Cash and cash equivalents at end of period | 41,094 | 30,292 |
